LifeClean International (LCLEAN) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 was 9,365 TSEK, down from 13,930 TSEK year-over-year; nine-month revenue was 44,438 TSEK, down from 50,718 TSEK.

• Adjusted EBITDA for Q3 was -6,713 TSEK (vs. -5,831 TSEK); EBITDA was -7,455 TSEK (vs. -10,242 TSEK); operating loss improved to -9,939 TSEK (vs. -12,531 TSEK).

• Cost-saving measures reduced operating expenses significantly, supporting improved results despite lower sales.

• Key regulatory milestones achieved, including EU biocide approval and new patents for PFAS remediation.

Financial highlights

• Q3 net sales: 9,365 TSEK (down 33% year-over-year); nine-month net sales: 44,438 TSEK (down 12%).

• Q3 adjusted EBITDA: -6,713 TSEK; Q3 EBITDA: -7,455 TSEK; Q3 operating result: -9,939 TSEK.

• Cash flow from operations in Q3: -6,331 TSEK (improved from -9,856 TSEK); nine-month cash flow: -22,269 TSEK.

• Cash at period end: 14,380 TSEK; available funds including credit: 21,180 TSEK.

• Equity at period end: 12,069 TSEK; net debt: 15,530 TSEK; equity ratio: 21%.

Outlook and guidance

• Available liquidity expected to fund operations into 2026 at current revenue levels.

• Additional financing may be required if sales do not reach sufficient levels; board believes new funding is feasible.